Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v5-EN
Language English English
Date Updated 2021-10-20 2021-09-08
Drug Identification Number 02483327 02483327
Brand name ACTEMRA ACTEMRA
Common or Proper name ACTEMRA ACTEMRA
Company Name HOFFMANN-LA ROCHE LIMITED HOFFMANN-LA ROCHE LIMITED
Ingredients TOCILIZUMAB TOCILIZUMAB
Strength(s) 162MG 162MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size Autoinjector Autoinjector
ATC code L04AC L04AC
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2021-10-31 2021-10-20
Actual start date
Estimated end date 2021-12-31 2021-12-31
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments During the COVID-19 pandemic, the demand for Actemra has been increasing at a global level. Roche has started to apply mitigation strategies to support our efforts to increase the supply of Actemra. During the COVID-19 pandemic, the demand for Actemra has been increasing at a global level. Roche has started to apply mitigation strategies to support our efforts to increase the supply of Actemra.
Health Canada comments